These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 26688184

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
    Sokolowska-Wojdylo M, Florek A, Zaucha JM, Chmielowska E, Giza A, Knopinska-Posluszny W, Kulikowski W, Prejzner W, Romejko-Jarosinska J, Paszkiewicz-Kozik E, Osowiecki M, Walewski J, Rogowski W, Grzanka A, Placek W, Lugowska-Umer H, Kowalczyk A, Nowicki R, Jurczak W.
    Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
    [Abstract] [Full Text] [Related]

  • 3. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma.
    Huen AO, Kim EJ.
    Dermatol Clin; 2015 Oct; 33(4):715-29. PubMed ID: 26433844
    [Abstract] [Full Text] [Related]

  • 4. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA, Davis MD, el-Azhary RA, McEvoy MT, Gibson LE, Knudsen JM, Kist JM, Pittelkow MR.
    J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
    [Abstract] [Full Text] [Related]

  • 5. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
    Izu-Belloso R, Gainza-Apraiz I, Ortiz-Romero P, Servitje-Bedate O, Fernández de Misa-Cabrera R, Peñate Y, Hernandez-Machin B, Estrach-Panella T, Llamas-Velasco M, Yanguas-Bayona JI, Morillo-Andujar M, Acebo-Mariñas E, Perez-Gala S, Armario-Hita JC, Sanchez-Sambucety P, Ortiz-Brugues A, Eguren-Michelena C, Bielsa-Marsol I, Lopez-Pestaña A, Blanes-Martinez M, Fernandez-Guarino M, Lopez-Lerma I.
    Actas Dermosifiliogr; 2024 Jun; 115(6):547-554. PubMed ID: 38395224
    [Abstract] [Full Text] [Related]

  • 6. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
    Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, Cowan R, Gallop-Evans E, Wachsmuth R, Eagle M, Wierzbicki AS, Soran H, Whittaker S, Wain EM.
    Br J Dermatol; 2013 Jan; 168(1):192-200. PubMed ID: 22963233
    [Abstract] [Full Text] [Related]

  • 7. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ.
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [Abstract] [Full Text] [Related]

  • 8. CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
    Gopaluni S, Perzova R, Abbott L, Farah R, Shrimpton A, Hutchison R, Poiesz BJ.
    Am J Hematol; 2008 Sep; 83(9):744-6. PubMed ID: 18615708
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Bexarotene therapy in folliculotropic cutaneous T-cell lymphoma].
    Drugeon C, Charlat I, Boulinguez S, Viraben R.
    Ann Dermatol Venereol; 2007 Sep; 134(8-9):639-43. PubMed ID: 17925686
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma.
    Sherman SI.
    Clin Lymphoma; 2003 Mar; 3(4):249-52. PubMed ID: 12672276
    [Abstract] [Full Text] [Related]

  • 13. Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy.
    Basani S, Garg A.
    J Clin Lipidol; 2015 Mar; 9(6):832-836. PubMed ID: 26687705
    [Abstract] [Full Text] [Related]

  • 14. Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
    Calderon Cabrera C, de la Cruz Vicente F, Marín-Niebla A, Carrillo Cruz E, Rios Herranz E, Espigado Tocino I, Prats Martín C, Falantes JF, Martino Galiana ML, Perez-Simón JA.
    Br J Haematol; 2013 Jul; 162(1):130-2. PubMed ID: 23581433
    [No Abstract] [Full Text] [Related]

  • 15. [Central hypothyroidism associated with bexarotene therapy].
    Martin C, Bach-Ngohou K, Perrin B, Masson D.
    Ann Biol Clin (Paris); 2006 Jul; 64(4):331-4. PubMed ID: 16829476
    [Abstract] [Full Text] [Related]

  • 16. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
    Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M, Lebbé C, Assaf C, Squier M, Williams D, Marshood M, Tai F, Prince HM.
    Eur J Cancer; 2013 Jan; 49(2):386-94. PubMed ID: 22981498
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
    Bohmeyer J, Stadler R, Kremer A, Nashan D, Muche M, Gellrich S, Luger T, Sterry W.
    J Dtsch Dermatol Ges; 2003 Oct; 1(10):785-9. PubMed ID: 16281814
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP, Levitan D, Fleischer AB.
    J Dermatolog Treat; 2009 Oct; 20(3):169-76. PubMed ID: 19016373
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.